These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 27488725)

  • 1. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
    Resetca D; Neschadim A; Medin JA
    J Immunother; 2016 Sep; 39(7):249-59. PubMed ID: 27488725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.
    Zhang E; Xu H
    J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cells for cancer immunotherapy.
    Gschweng E; De Oliveira S; Kohn DB
    Immunol Rev; 2014 Jan; 257(1):237-49. PubMed ID: 24329801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
    Morgan MA; Schambach A
    Front Immunol; 2018; 9():2493. PubMed ID: 30420856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-modified T cells strike back.
    Frigault MJ; Maus MV
    Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
    Badieyan ZS; Hoseini SS
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
    Ren YB; Sun SJ; Han SY
    Curr Pharm Des; 2018; 24(1):78-83. PubMed ID: 29283058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of genetic modification of T cells for cancer treatment.
    Dotti G; Heslop HE
    Cytotherapy; 2005; 7(3):262-72. PubMed ID: 16081353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T-cell therapy of solid tumors.
    Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
    Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
    Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
    Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.